New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Abstract Objective Atopic dermatitis (AD) is an increasingly common inflammatory skin disease undergoing significant revolution in recent years. New data on disease pathogenesis advanced the developments of novel therapeutics, mainly for patients with moderate to severe conditions, for whom treatment options have been largely insufficient for many years. Data Sources Review of recent studies investigating systemic treatments for AD. Study Selections Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized. Results Multiple clinical trials of both nonspecific as well as specific agents revealed favorable outcomes in AD, including JAK inhibitors, a dual JAK/SYK inhibitor, a histamine H4R antagonist, antagonists of the TSLP/OX40L axis, an IL-22 inhibitor, and IL-33 and IL-17C antagonists. Importantly, negative trials were published as well (eg, phosphodiesterase 4 inhibitor, apremilast). Conclusion In this rapidly evolving field of AD treatments, a completely new treatment paradigm will be available in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
The SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627
Self-citationAnti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Ramirez-Carrozzi, V., Sambandam, A., Luis, E., Lin, Z., Jeet, S., Lesch, J., Hackney, J., Kim, J., Zhou, M., Lai, J., et al. (2011) · Nature Immunology · doi:10.1038/ni.2156 · Cited by 477
Cited by
Metabolic orchestration of the wound healing response
Eming, S. A., Murray, P. J., & Pearce, E. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.017 · Cited by 315
Reich, K., Kabashima, K., Peris, K., Silverberg, J. I., Eichenfield, L. F., Bieber, T., Kaszuba, A., Kolodsick, J., Yang, F. E., Gamalo, M., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3260 · Cited by 285
Cutaneous barrier dysfunction in allergic diseases
Leung, D. Y. M., Berdyshev, E., & Goleva, E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.02.021 · Cited by 190
“Although cytokines such as interferon gamma, IL-17, and IL-22 can modify the course of allergic responses, Type 2 cytokines such as IL-4, IL-13, TSLP, and IL-33 play a central role in the development of allergic diseases (6,7).”
BackgroundEfficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
Self-citationPiscitelli, S. C., Pavel, A. B., McHale, K., Jett, J. E., Collins, J., Gillmor, D., Tabolt, G., Li, R., Song, T., Zhang, N., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.031 · Cited by 30
Self-citation
Metadata
- Authors
- Renert-Yuval, Y., & Guttman-Yassky, E.
- Venue
- Annals of Allergy, Asthma & Immunology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 124
- Issue
- 1
- Pages
- 28-35
- ISSN
- 1081-1206 (ISSN-L)
- OpenAlex
- W2980943823
- Cited by
- 125
- References
- 18
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. https://app.cochat.ai/papers/10.1016/j.anai.2019.10.005
- The paper
- Renert-Yuval, Y., & Guttman-Yassky, E. (2020). New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2019.10.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.